Shire gets extended market authorization in Europe for drug to treat children with a rare gastrointestinal condition
July 7, 2016Research and Development, Sales and Marketing European Commission, Revestive, Shire, market authorisation, short bowel syndrome
UK drugmaker Shire (LSE: SHP) said the European Commission has granted extension of Market Authorization for Revestive (teduglutide) to treat …
Pfizer’s blood cancer drug first to be reappraised from Cancer Drug Fund
July 7, 2016Research and Development, Sales and Marketing Cancer, Cancer Drugs Fund, NICE, Pfizer, blood cancer, bosulif
The National Institute for Health and Care Excellence (Nice) recommended US pharma giant Pfizer’s (NYSE: PFE) Bosulif (bosutinib) to treat …
Takeda says its cancer drug Adcetris gets European backing in for hodgkin lymphoma
July 6, 2016Research and Development European Commission, Takeda, drug trial, lymphoma
Takeda Pharmaceutical (TSE: 4502) said the European Commission has extended the marketing authorization for its Adcetris (brentuximab vedotin) to treat …
Merck and Pfizer begin Phase III trials for avelumab in ovarian cancer
July 6, 2016Research and Development Merck, Pfizer, avelumab
Merck (KGaA, Darmstadt) and Pfizer (NYSE: PFE) have announced the initiation of the first Phase III study of investigational compound, …
Wickham Laboratories Announces New In Vitro Pyrogenicity Testing Method
July 6, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
Wickham Laboratories is pleased to announce the introduction of a new in vitro test method, the Monocyte Activation Test, for …
AstraZeneca trigger $10 million milestone payment for Heptares in immuno-oncology candidate
July 6, 2016Research and Development, Sales and Marketing AstraZeneca, Heptares
AstraZeneca (LSE: AZN) is set to deliver a payment of $10 million to Heptares Therapeutics after the first patient was …
Sanofi says to co-develop Zika vaccine with US government
July 6, 2016Research and Development, Sales and Marketing Sanofi, US government, Vaccine, Zika virus, drug development, research
French drugmaker Sanofi (Euronext: SAN) said it will co-develop a Zika vaccine candidate with the US government. No financial details …
Bristol-Myers Squibb acquires Cormorant Pharmaceuticals in deal worth up to $425 million
July 6, 2016Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, cormorant
Bristol-Myers Squibb (NYSE: BMY) has announced that it has acquired all outstanding capital stock of Sweden-based Cormorant Pharmaceuticals, granting it …
Sanofi signs confidentiality agreement with Medivation for due diligence access for potential deal
July 6, 2016Research and Development, Sales and Marketing Financial, M&A, MA, Medivation, Sanofi, deal, offer
Sanofi (Euronext: SAN) confirmed it has entered a confidentiality agreement with cancer drugmaker Medivation (Nasdaq: MDVN) under which it will …
Nice rejects BMS’ immunotherapy Opdivo for previously treated kidney cancer on pricing
July 5, 2016Manufacturing and Production, Research and Development, Sales and Marketing Bristol-Myers Squibb, NICE, QALY, immunotherapy, opdivo, regulation
UK regulators have rejected Bristol-Myers Squibb’s (NYSE: BMY) immunotherapy Opdivo for previously treated kidney cancer on pricing and substantial uncertainty …
UCB scores Japanese approval for seizure therapy, Vimpat
July 5, 2016Manufacturing and Production, Research and Development Daiichi Sankyo, Japan, UCB, japanese
UCB Biopharma (EURONEXT: UCB) and Daiichi Sankyo have announced that Vimpat (lacosamide) has been approved as an adjunctive therapy in …
Sanofi, Regeneron say cholesterol drug Praluent approved in Japan
July 5, 2016Manufacturing and Production, Research and Development, Sales and Marketing Japan, Regeneron, Sanofi, cardiovascular, cholestrol, praleunt
Sanofi (Euronext: SAN) and Regeneron Pharmaceuticals (Nasdaq: REGN) said the lawmakers in Japan have granted marketing and manufacturing authorization for …
Eisai launches cancer drug Lenvatinib in Mexico
July 4, 2016Research and Development, Sales and Marketing Cancer, Eisai, Mexico, lenvatinib, product launch
Japanese drug firm Eisai Co (TYO: 4523) said it has launched its anticancer agent Lenvima (lenvatinib mesylate) in Mexico. Lenvima …
Allergan says its double chin correction therapy Belkyra gets positive opinion from Swedish regulators
July 4, 2016Research and Development, Sales and Marketing Allergan, Belkyra, Botox, EU, Sweden, double chin, drug trial
Botox maker Allergan (NYSE: AGN) said it has received a positive opinion from the Swedish Medical Products Agency for its …
Amgen says its blood cancer drug gets European backing for extended indication
July 4, 2016Research and Development, Sales and Marketing Amgen, European Commission, Kyprolis, blood cancer, drug trial
Amgen (Nasdaq: AMGN) said the European Commission (EC) has approved a variation to the marketing authorization for its Kyprolis (carfilzomib) to include use …
Merck says its Erbitux in combination with Folfox improves outcomes in colorectal cancer
July 4, 2016Research and Development, Sales and Marketing Cancer, China, ESMO, Merck, colorectal cancer, drug trial, research, study
Merck said late-stage trials for its Erbitux (cetuximab) in combination with Folfox significantly improved progression free survival in metastatic colorectal …
Weekly Movers: Regulus, Nymox, Akers…
July 4, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Shares, drug trial, markets, stocks
Shares in Regulus Therapeutics (Nasdaq: RGLS) dropped after the company said it has received verbal notification from the US Food …
AstraZeneca licenses skin-condition drug to Leo Pharma for $115 million upfront
July 1, 2016Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Deals, Licencing, Loe Pharna, Valeant, drug development
UK drug firm AstraZeneca (LSE: AZN) said it has licenced its drug for skin diseases to Leo Pharma for an …
US doctors received $6.5 billion from drug, device firms in 2015
July 1, 2016Medical Communications, Research and Development, Sales and Marketing US, affordable care act, pharma, regulation
Doctors and hospitals received nearly $6.5 billion in research and speaking fees as well as other goods or services from …
UK healthcare professionals received £340.3 million in benefits from pharma industry in 2015 discloses ABPI
July 1, 2016Business Services, Medical Communications, Sales and Marketing ABPI, Pharmacutical, corruption, disclosure, regulation
“We don’t want our neighbours to know what we earn,” said Mike Thompson, the chief executive of industry body Association …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
